| CAS NO: | 66611-38-9 |
| 规格: | ≥98% |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 250mg | 电议 |
| 500mg | 电议 |
| Molecular Weight (MW) | 351.27 |
|---|---|
| Formula | C14H24Cl2N4O2 |
| CAS No. | 66611-37-8 |
| Storage | -20℃ for 3 years in powder form |
| -80℃ for 2 years in solvent | |
| Solubility (In vitro) | DMSO: 11.33 mg/mL |
| Water: N/A | |
| Ethanol: N/A | |
| Other info | Chemical Name: N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidamide SMILES Code: N=C(NOCC(O)CN1CCCCC1)C2=CN=CC=C2 |
| Synonyms | BGP15; BGP-15; BGP 15; BGP15 hydrochloride; BGP15 HCl; N-(2-hydroxy-3-(piperidin-1-yl)propoxy)nicotinimidamide dihydrochloride |
| In Vitro | In vitro activity: BGP-15 (200 μM) prevents the imatinib mesylate-induced oxidative damages, attenuates the depletion of high-energy phosphates, alters the signaling effect of imatinib mesylate by preventing p38 MAP kinase and JNK activation, and induced the phosphorylation of Akt and GSK-3beta. Cell Assay: Previous study showed that BGP-15 at 200 μM could prevent the imatinib-induced oxidative damages, attenuate the depletion of high-energy phosphates, alter the signaling effect of imatinib by preventing p38 MAP kinase and JNK activation, and also induce the Akt and GSK-3β phosphorylation. |
|---|---|
| In Vivo | BGP-15 (15 mg/kg, p.o.) does not improve skeletal muscle pathology in older mdx mice. In a rat model, 10 days of BGP-15 treatment greatly improves diaphragm muscle fiber function (by about 100%), although it does not reverse diaphragm atrophy. The treatment also provides protection from myosin PTMs associated with HSP72 induction and PARP-1 inhibition, resulting in improvement of mitochondrial function and content. BGP-15 (15 mg/kg per day in saline) treatment has no effect in Ntg mice or an independent cohort of normal adult wild-type mice based on morphology, cardiac function and ECG parameters. Treatment with BGP-15 attenuates the increase in atrial size and lung weight. BGP-15 treatment is able to prevent or reduce episodes of arrhythmia. BGP-15 treatment is associated with a reduced PR interval in the HF+AF model. |
| Animal model | Mice |
| Formulation & Dosage | 15 mg/kg, p.o. |
| References | Am J Pathol. 2016 Dec;186(12):3246-3260; Sci Transl Med. 2016 Aug 3;8(350):350ra103; Nat Commun. 2014 Dec 9;5:5705. |
m.cnreagent.com